A Phase I, Randomized, Blinding, Single-dose, Placebo Control Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics Effect of GR2002 in Chinese Health Volunteers
Latest Information Update: 26 Aug 2024
At a glance
- Drugs GR 2002 (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Genrix (Shanghai) Biopharmaceuticals
- 22 Aug 2024 Status changed from recruiting to completed.
- 27 Jul 2023 New trial record